Marker Therapeutics (MRKR) Competitors $3.38 -0.04 (-1.17%) (As of 12/24/2024 05:10 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends MRKR vs. SAVA, CABA, IVA, LPTX, TARA, ANRO, XFOR, ABOS, EDIT, and MNOVShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Cassava Sciences (SAVA), Cabaletta Bio (CABA), Inventiva (IVA), Leap Therapeutics (LPTX), Protara Therapeutics (TARA), Alto Neuroscience (ANRO), X4 Pharmaceuticals (XFOR), Acumen Pharmaceuticals (ABOS), Editas Medicine (EDIT), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Cassava Sciences Cabaletta Bio Inventiva Leap Therapeutics Protara Therapeutics Alto Neuroscience X4 Pharmaceuticals Acumen Pharmaceuticals Editas Medicine MediciNova Marker Therapeutics (NASDAQ:MRKR) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership. Do institutionals and insiders believe in MRKR or SAVA? 22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 17.4% of Marker Therapeutics shares are held by insiders. Comparatively, 12.2% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MRKR or SAVA? Cassava Sciences received 26 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 65.33% of users gave Cassava Sciences an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformMarker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Cassava SciencesOutperform Votes9865.33% Underperform Votes5234.67% Which has more volatility & risk, MRKR or SAVA? Marker Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.85, suggesting that its share price is 185% less volatile than the S&P 500. Is MRKR or SAVA more profitable? Cassava Sciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Cassava Sciences' return on equity of -88.05% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Marker Therapeutics-179.74% -89.63% -71.62% Cassava Sciences N/A -88.05%-64.98% Does the media favor MRKR or SAVA? In the previous week, Cassava Sciences had 20 more articles in the media than Marker Therapeutics. MarketBeat recorded 25 mentions for Cassava Sciences and 5 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.93 beat Cassava Sciences' score of 0.08 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 5 Very Positive mention(s) 1 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer MRKR or SAVA? Marker Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 462.13%. Cassava Sciences has a consensus price target of $111.50, indicating a potential upside of 4,664.96%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings and valuation, MRKR or SAVA? Marker Therapeutics has higher revenue and earnings than Cassava Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarker Therapeutics$3.31M9.11-$8.24MN/AN/ACassava SciencesN/AN/A-$97.22M-$1.38-1.70 SummaryCassava Sciences beats Marker Therapeutics on 8 of the 14 factors compared between the two stocks. Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.16M$6.71B$5.22B$9.27BDividend YieldN/A3.00%5.12%4.29%P/E RatioN/A10.5487.3417.27Price / Sales9.11195.831,166.41119.60Price / CashN/A57.1543.2337.83Price / Book2.145.164.834.93Net Income-$8.24M$151.58M$120.46M$225.34M7 Day Performance-16.13%4.12%2.84%4.14%1 Month Performance1.50%-3.99%19.70%1.16%1 Year Performance-14.86%10.33%30.57%16.98% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics4.4471 of 5 stars$3.38-1.2%$19.00+462.1%-14.9%$30.16M$3.31M0.0060Insider TradeNews CoverageHigh Trading VolumeSAVACassava Sciences4.4729 of 5 stars$2.43+3.4%$111.50+4,488.5%-90.2%$116.91MN/A-1.7630CABACabaletta Bio2.676 of 5 stars$2.37-0.4%$24.38+928.5%-89.4%$115.84MN/A-1.1050IVAInventiva2.638 of 5 stars$2.17-7.7%$13.25+510.6%-51.3%$113.88M$15.62M0.00100News CoverageLPTXLeap Therapeutics1.2089 of 5 stars$2.85-2.1%$7.50+163.2%-10.2%$109.21M$1.50M-1.4840TARAProtara Therapeutics2.0763 of 5 stars$5.17-4.1%$22.67+338.4%+182.5%$106.66MN/A-1.8330Gap DownANROAlto Neuroscience3.3178 of 5 stars$3.95+1.5%$20.00+406.3%N/A$106.53M$210,000.000.00N/AGap UpXFORX4 Pharmaceuticals4.0403 of 5 stars$0.62+2.1%$3.50+460.8%-19.8%$106.44M$1.12M-6.9380ABOSAcumen Pharmaceuticals3.2184 of 5 stars$1.76-4.9%$9.33+430.3%-49.9%$105.74MN/A-1.2851Positive NewsEDITEditas Medicine4.4427 of 5 stars$1.27-3.4%$7.00+453.4%-88.8%$104.42M$61.76M-0.49230MNOVMediciNova2.0231 of 5 stars$2.12-2.3%$9.00+324.5%+41.8%$103.98M$1M-10.0910Analyst ForecastPositive News Related Companies and Tools Related Companies Cassava Sciences Alternatives Cabaletta Bio Alternatives Inventiva Alternatives Leap Therapeutics Alternatives Protara Therapeutics Alternatives Alto Neuroscience Alternatives X4 Pharmaceuticals Alternatives Acumen Pharmaceuticals Alternatives Editas Medicine Alternatives MediciNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRKR) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
